RxSight CFO Mark Wilterding sells $54,044 in company stock

Mark Wilterding, Chief Financial Officer of RxSight, Inc. (NASDAQ:RXST), sold 7,765 shares of the company’s common stock on September 2, 2026. The shares were sold at a price of $6.96 per share, totaling $54,044. The stock currently trades at $7.03, with a market cap of $292 million. According to InvestingPro analysis, RXST appears undervalued at current levels, with a Fair Value of $8.62.

This transaction followed the acquisition of 20,441 shares of common stock on August 31, 2026, through the vesting of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of RxSight’s common stock.

The sale of shares was reported as representing the number of shares sold to cover tax withholding obligations in connection with the RSU vesting, and it was not a discretionary sale by Mr. Wilterding.

Following these reported transactions, Mr. Wilterding directly holds 25,049 shares of common stock and 122,646 restricted stock units. For deeper insights into RXST’s financial health and valuation, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.

In other recent news, RxSight reported second-quarter 2026 results that exceeded Wall Street expectations. The company posted an adjusted earnings loss of $0.11 per share, significantly better than the anticipated loss of $0.36. Revenue for the quarter was $33.74 million, surpassing the forecasted $32.21 million. Despite these positive results, RxSight withdrew its full-year guidance, citing ongoing challenges in its core business. In related developments, Stifel lowered its price target for RxSight from $8.00 to $7.00, maintaining a Hold rating on the shares. This adjustment follows the company’s pre-announcement of weak second-quarter results and a collaboration announcement with ALC. Stifel’s analyst noted that the withdrawal of guidance does not indicate worsening trends, as conditions have improved quarter-to-date. These developments highlight the mixed signals investors are receiving regarding RxSight’s financial health and future prospects.